Targeting of nucleo‑cytoplasmic transport factor exportin 1 in malignancy (Review)
- Authors:
- Sibel Özdaş
- İpek Canatar
-
Affiliations: Department of Bioengineering, Faculty of Engineering Sciences, Adana Alparslan Türkeş Science and Technology University, Adana 01250, Turkey - Published online on: December 28, 2021 https://doi.org/10.3892/mi.2021.27
- Article Number: 2
-
Copyright : © Özdaş et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Abstract
 |
|
Wente SR: Gatekeepers of the nucleus. Science. 288:1374–1377. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Watson J, Baker T, Bell S, Gann A, Levine M and Losick R: Molecular Biology of the Gene. 5th ed. Pearson/Benjamin Cummings: San Francisco Cold Spring Harbor, NY, 912 p. 2004. | |
|
Izaurralde E and Adam S: Transport of macromolecules between the nucleus and the cytoplasm. RNA. 4:351–364. 1998.PubMed/NCBI | |
|
Misteli T: Physiological importance of RNA and protein mobility in the cell nucleus. Histochem Cell Biol. 129:5–11. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Chook YM and Blobel G: Karyopherins and nuclear import. Curr Opin Struct Biol. 11:703–715. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Alberts B, Johnson A, Lewis J, Raff M, Roberts K and Walter P: Drosophila and the Molecular Genetics of Pattern Formation: Genesis of the Body Plan. 4th edition. Garland Science, New York, NY, 2002. | |
|
La Cour T, Kiemer L, Mølgaard A, Gupta R, Skriver K and Brunak S: Analysis and prediction of leucine-rich nuclear export signals. Protein Eng Des Sel. 17:527–536. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B and Kinzler KW: APC mutations occur early during colorectal tumorigenesis. Nature. 359:235–237. 1992.PubMed/NCBI View Article : Google Scholar | |
|
Pichler A and Melchior F: Ubiquitin-related modifier SUMO1 and nucleocytoplasmic transport. Traffic. 3:381–387. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Azmi S, Uddin MH and Mohammad RM: The nuclear export protein XPO1 - from biology to targeted therapy. Nat Rev Clin Oncol. 18:152–169. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Pemberton LF and Paschal BM: Mechanisms of receptor-mediated nuclear import and nuclear export. Traffic. 6:187–198. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Kau TR, Way JC and Silver PA: Nuclear transport and cancer: From mechanism to intervention. Nat Rev Cancer. 4:106–117. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Fornerod M, Ohno M, Yoshida M and Mattaj IW: CRM1 is an export receptor for leucine-rich nuclear export signals. Cell. 90:1051–1060. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Kudo N, Khochbin S, Nishi K, Kitano K, Yanagida M, Yoshida M and Horinouchi S: Molecular cloning and cell cycle-dependent expression of mammalian CRM1, a protein involved in nuclear export of proteins. J Biol Chem. 272:29742–29751. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Adachi Y and Yanagida M: Higher order chromosome structure is affected by cold-sensitive mutations in a Schizosaccharomyces pombe gene crm1+ which encodes a 115-kD protein preferentially localized in the nucleus and its periphery. J Cell Biol. 108:1195–1207. 1989.PubMed/NCBI View Article : Google Scholar | |
|
Ruggiero A, Giubettini M and Lavia P: XPO1 (exportin 1 (CRM1 homolog, yeast)). Atlas of Genetics and Cytogenetics in Oncology and Haematology. INIST-CNRS 16: 2011. | |
|
Fornerod M, van Baal S, Valentine V, Shapiro DN and Grosveld G: Chromosomal localization of genes encoding CAN/Nup214-interacting proteins-human CRM1 localizes to 2p16, whereas Nup88 localizes to 17p13 and is physically linked to SF2p32. Genomics. 42:538–540. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Parikh K, Cang S, Sekhri A and Liu D: Selective inhibitors of nuclear export (SINE)-a novel class of anti-cancer agents. J Hematol Oncol. 7(78)2014.PubMed/NCBI View Article : Google Scholar | |
|
Fornerod M, Van Deursen J, Van Baal S, Reynolds A, Davis D, Murti KG, Fransen J and Grosveld G: The human homologue of yeast CRM1 is in a dynamic subcomplex with CAN/Nup214 and a novel nuclear pore component Nup88. EMBO J. 16:807–816. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Petosa C, Schoehn G, Askjaer P, Bauer U, Moulin M, Steuerwald U, Soler-Lopez M, Baudin F, Mattaj IW and Müller CW: Architecture of CRM1/Exportin1 suggests how cooperativity is achieved during formation of a nuclear export complex. Mol Cell. 16:761–775. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Dölker N, Blanchet CE, Voss B, Haselbach D, Kappel C, Monecke T, Svergun DI, Stark H, Ficner R, Zachariae U, et al: Structural determinants and mechanism of mammalian CRM1 allostery. Structure. 21:1350–1360. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Saito N and Matsuura YA: 2.1-Å-resolution crystal structure of unliganded CRM1 reveals the mechanism of autoinhibition. J Mol Biol. 425:350–364. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Koyama M and Matsuura Y: An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1. EMBO J. 29:2002–1013. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Lee SH and Hannink M: The N-terminal nuclear export sequence of IkappaBalpha is required for RanGTP-dependent binding to CRM1. J Biol Chem. 276:23599–23606. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Dong X, Biswas A, Süel KE, Jackson LK, Martinez R, Gu H and Chook YM: Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature. 458:1136–1141. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Ptasznik A, Nakat Y, Kalota A, Emerson SG and Gewirtz AM: Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med. 10:1187–1189. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Grunewald TG, Kammerer U, Schulze E, Schindler D, Honig A, Zimmer M and Butt E: Silencing of LASP-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells. Exp Cell Res. 312:974–982. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, Yanagida M and Nishida E: CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature. 390:308–311. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Ossareh-Nazari B, Bachelerie F and Dargemont C: Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science. 278:141–144. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Fei E, Ma X, Zhu C, Xue T, Yan J, Xu Y, Zhou J and Wang G: Nucleocytoplasmic shuttling of dysbindin-1, a schizophrenia-related protein, regulates synapsin I expression. J Biol Chem. 285:38630–38640. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Matsuyama A, Arai R, Yashiroda Y, Shirai A, Kamata A, Sekido S, Kobyashi Y, Hashimoto A, Hamamoto M, Hiraoka Y, et al: ORFeome cloning and global analysis of protein localization in the fission yeast Schizosaccharomyces pombe. Nat Biotechnol. 24:841–847. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Kutay U and Güttinger S: Leucine-rich nuclear-export signals: Born to be weak. Trends Cell Biol. 15:121–124. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Turner JG, Dawson J and Sullivan DM: Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol. 83:1021–1032. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Vogt PK, Jiang H and Aoki M: Triple layer control: Phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle. 4:908–913. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Craig E, Zhang ZK, Davies KP and Kalpana GV: A masked NES in INI1/hSNF5 mediates hCRM1-dependent nuclear export: Implications for tumorigenesis. EMBO J. 21:31–42. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Yoneda Y, Hieda M, Nagoshi E and Miyamoto Y: Nucleocytoplasmic protein transport and recycling of Ran. Cell Struct Funct. 24:425–333. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Poon IK and Jans DA: Regulation of nuclear transport: Central role in development and transformation? Traffic. 6:173–186. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Gandhi UH, Senapedis W, Baloglu E, Unger TJ, Chari A, Vogl D and Cornell RF: Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma. Clin Lymphoma Myeloma Leuk. 18:335–345. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Fabbro M and Henderson BR: Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res. 282:59–69. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Rensen WM, Mangiacasale R, Ciciarello M and Lavia P: The GTPase Ran: Regulation of cell life and potential roles in cell transformation. Front Biosci. 13:4097–4121. 2008.PubMed/NCBI View Article : Google Scholar | |
|
van der Watt PJ and Leaner VD: The nuclear exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to DNA damage. Biochim Biophys Acta. 1809:316–326. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X, Sato Y, Okuno Y, Varela AM, Ding LW, et al: Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet. 46:467–473. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, et al: Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 152:714–726. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Liu X, Malenfant P, Reesor C, Lee A, Hudson ML, Harvard C, Qiao Y, Persico AM, Cohen IL, Chudley AE, et al: 2p15-p16. 1 microdeletion syndrome: Molecular characterization and association of the OTX1 and XPO1 genes with autism spectrum disorders. Eur J Hum Genet. 19:1264–1270. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Pernat Drobež C, Repnik K, Gorenjak M, Ferkolj I, Weersma RK and Potocnik U: DNA polymorphisms predict time to progression from uncomplicated to complicated Crohn's disease. Eur J Gastroenterol Hepatol. 30:447–455. 2018.PubMed/NCBI View Article : Google Scholar | |
|
He X, Zhang H, Tao B, Yang M, Chen H, Lu L, Yi H, Pan H and Tang S: The A/A genotype of XPO1 rs4430924 is associated with higher risk of antituberculosis drug-induced hepatotoxicity in Chinese patients. J Clin Pharmacol. 59:1014–1021. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Noske A, Weichert W, Niesporek S, Röske A, Buckendahl AC, Koch I, Sehouli J, Dietel M and Denkert C: Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer. 112:1733–1743. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, Birrer MJ and Leaner VD: The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer. 124:1829–1840. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Liu X, Chong Y, Tu Y, Liu N, Yue C, Qi Z, Liu H, Yao Y, Liu H, Gao S, et al: CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways. J Hematol Oncol. 9(108)2016.PubMed/NCBI View Article : Google Scholar | |
|
Jiang Y, Hou J, Zhang X, Xu G, Wang Y, Shen L, Wu Y, Li Y and Yao L: Circ-XPO1 upregulates XPO1 expression by sponging multiple miRNAs to facilitate osteosarcoma cell progression. Exp Mol Pathol. 117(104553)2020.PubMed/NCBI View Article : Google Scholar | |
|
Azmi AS, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman MG, Philip PA and Mohammad RM: Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. Oncotarget. 8:82144–82155. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Van der Watt PJ, Zemanay W, Govender D, Hendricks DT, Parker MI and Leaner VD: Elevated expression of the nuclear export protein, Crm1 (exportin 1), associates with human esophageal squamous cell carcinoma. Oncol Rep. 32:730–738. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Yang X, Cheng L, Yao L, Ren H, Zhang S, Min X, Chen X, Zhang J and Li M: Involvement of chromosome region maintenance 1 (CRM1) in the formation and progression of esophageal squamous cell carcinoma. Med Oncol. 31(155)2014.PubMed/NCBI View Article : Google Scholar | |
|
Liu Z and Ga W: Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 335:16–27. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Sexton R, Mahdi Z, Chaudhury R, Beydoun R, Aboukameel A, Khan HY, Baloglu E, Senapedis W, Landesman Y, Tesfaye A, et al: Targeting nuclear exporter protein XPO1/CRM1 in gastric cancer. Int J Mol Sci. 20(4826)2019.PubMed/NCBI View Article : Google Scholar | |
|
Özdaş S and Özdaş T: Crm1 knockdown by specific small interfering RNA reduces cell proliferation and induces apoptosis in head and neck cancer cell lines. Turk J Biol. 42:132–143. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Özdaş S: Nuclear entrapment of p33ING1b by inhibition of exportin-1: A trigger of apoptosis in head and neck squamous cell cancer. Cell Mol Biol (Noisy-le-grand). 64:66–72. 2018.PubMed/NCBI | |
|
Inoue H, Kauffman M, Shacham S, Landesman Y, Yang J, Evans CP and Weiss RH: CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol. 189:2317–2326. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Zheng Y, Gery S, Sun H, Shacham S, Kauffman M and Koeffler HP: KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma. Cancer Chemother Pharmacol. 74:487–495. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Conway AE, Haldeman JM, Wechsler DS and Lava CP: A critical role for CRM1 in regulating HOXA gene transcription in CALM-AF10 leukemias. Leukemia. 29:423–432. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, et al: Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 121:4166–4174. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, et al: Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood. 120:4621–4634. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, Zhang L, Ou Z, Li C, Sun L, et al: Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol. 41:67–78.e4. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quintás-Cardama A, McDonnell TJ, Neelapu SS, Kwak LW, Shacham S, Kauffman M, et al: Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO 1) inhibition in mantle cell lymphoma. Cancer Sci. 105:795–801. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi AA, et al: CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications. Leukemia. 28:155–165. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Wang AY, Weiner H, Green M, Chang H, Fulton N, Larson RA, Odenike O, Artz AS, Bishop MR, Godley LA, et al: A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol. 11(4)2018.PubMed/NCBI View Article : Google Scholar | |
|
Yue L, Sun ZN, Yao YS, Shen Z, Wang HB, Liu XP, Zhou F, Xiang JY, Yao RY and Niu HT: CRM1, a novel independent prognostic factor overexpressed in invasive breast carcinoma of poor prognosis. Oncol Lett. 15:7515–7522. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Dasso M: Ran at kinetochores. Biochem Soc Trans. 34:711–715. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Sendino M, Omaetxebarria MJ and Rodríguez JA: Hitting a moving target: Inhibition of the nuclear export receptor XPO1/CRM1 as a therapeutic approach in cancer. Cancer Drug Resistance. 1:139–163. 2018. | |
|
Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P and Sullivan DM: Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res. 69:6899–6905. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Takenaka Y, Fukumori T, Yoshii T, Oka N, Inohara H, Kim HR, Bresalier RS and Raz A: Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol. 24:4395–4406. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Aloisi A, Di Gregorio S, Stagno F, Guglielmo P, Mannino F, Sormani MP, Bruzzi P, Gambacorti-Passerini C, Saglio G, Venuta S, et al: BCR-ABL nuclear entrapment kills human CML cells: Ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood. 107:1591–1598. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Dickmanns A, Monecke T and Ficner R: Structural basis of targeting the exportin CRM1 in cancer. Cells. 4:538–568. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B, Yoshida M and Horinouchi S: Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA. 96:9112–9117. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Mutka SC, Yang WQ, Dong SD, Ward SL, Craig DA, Timmermans PB and Murli S: Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 69:510–517. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Newlands ES, Rustin GJ and Brampton MH: Phase I trial of elactocin. Br J Cancer. 74:648–649. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Hayakawa Y, Sohda KY, Shin-Ya K, Hidaka T and Seto H: Anguinomycins C and D, new antitumor antibiotics with selective cytotoxicity against transformed cells. J Antibiot (Tokyo). 48:954–961. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Wach JY, Güttinger S, Kutay U and Gademann K: The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport. Bioorg Med Chem Lett. 20:2843–2846. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Sophonnithiprasert T, Mahabusarakam W, Nakamura Y and Watanapokasin R: Goniothalamin induces mitochondria-mediated apoptosis associated with endoplasmic reticulum stress-induced activation of JNK in HeLa cells. Oncol Lett. 13:119–128. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Hilliard M, Frohnert C, Spillner C, Marcone S, Nath A, Lampe T, Fitzgerald DJ and Kehlenbach RH: The anti-inflammatory prostaglandin 15-deoxy-delta(12,14)-PGJ2 inhibits CRM1-dependent nuclear protein export. J Biol Chem. 285:22202–22210. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Muqbil I, Azmi AS and Mohammad RM: Nuclear export inhibition for pancreatic cancer therapy. Cancers (Basel). 10(138)2018.PubMed/NCBI View Article : Google Scholar | |
|
Liu X, Niu M, Xu X, Cai W, Zeng L, Zhou X, Yu R and Xu K: CRM1 is a direct cellular target of the natural anti-cancer agent plumbagin. J Pharmacol Sci. 124:486–493. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Niu M, Chong Y, Han Y and Liu X: Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells. Cancer Biol Ther. 16:1110–1118. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Niu M, Xu X, Shen Y, Yao Y, Qiao J, Zhu F, Zeng L, Liu X and Xu K: Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity. Chem Biol Interact. 237:66–72. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Meissner T, Krause E and Vinkemeier U: Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms. FEBS Lett. 576:27–30. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Fleta-Soriano E, Martinez JP, Hinkelmann B, Gerth K, Washausen P, Diez J, Frank R, Sasse F and Meyerhans A: The myxobacterial metabolite ratjadone A inhibits HIV infection by blocking the Rev/CRM1-mediated nuclear export pathway. Microb Cell Fact. 13(17)2014.PubMed/NCBI View Article : Google Scholar | |
|
Klahn P, Fetz V, Ritter A, Collisi W, Hinkelmann B, Arnold T, Tegge W, Rox K, Hüttel S, Mohr KI, et al: The nuclear export inhibitor aminoratjadone is a potent effector in extracellular-targeted drug conjugates. Chem Sci. 10:5197–5210. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Camus V, Miloudi H, Taly A, Sola B and Jardin F: XPO1 in B cell hematological malignancies: From recurrent somatic mutations to targeted therapy. J Hematol Oncol. 10(47)2017.PubMed/NCBI View Article : Google Scholar | |
|
Azmi AS, Muqbil I, Wu J, Aboukameel A, Senapedis W, Baloglu E, Bollig-Fischer A, Dyson G, Kauffman M, Landesman Y, et al: Targeting the nuclear export protein XPO1/CRM1 reverses epithelial to mesenchymal transition. Sci Rep. 5(16077)2015.PubMed/NCBI View Article : Google Scholar | |
|
Theodoropoulos N, Lancman G and Chari A: Targeting nuclear export proteins in multiple myeloma therapy. Target Oncol. 15:697–708. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Niu M, Wu S, Mao L and Yang Y: CRM1 is a cellular target of curcumin: New insights for the myriad of biological effects of an ancient spice. Traffic. 14:1042–1052. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, Conway AS, Chen WC, Reed C, Mansour MR, et al: Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. Leukemia. 30:190–199. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, et al: KPT-330 inhibitor of CRM 1 (XPO 1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 161:117–127. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Subhash VV, Yeo MS, Wang L, Tan SH, Wong FY, Thuya WL, Tan WL, Peethala PC, Soe MY, Tan DSP, et al: Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor. Sci Rep. 8(12248)2018.PubMed/NCBI View Article : Google Scholar | |
|
Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S and Festuccia C: Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol. 7(85)2014.PubMed/NCBI View Article : Google Scholar | |
|
Azizian NG and Li Y: XPO1-dependent nuclear export as a target for cancer therapy. J Hematol Oncol. 13(61)2020.PubMed/NCBI View Article : Google Scholar | |
|
Lewin J, Malone E, Al-Ezzi E, Fasih S, Pedersen P, Accardi S, Gupta A and Abdul Razak A: A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS). Eur J Cancer. 144:360–367. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Mendonca J, Sharma A, Kim HS, Hammers H, Meeker A, De Marzo A, Carducci M, Kauffman M, Shacham S and Kachhap S: Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer. Oncotarget. 5:6102–6112. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Uddin MH, Zonder JA and Azmi AS: Exportin 1 inhibition as antiviral therapy. Drug Discov Today. 25:1775–1781. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Han X, Wang J, Shen Y, Zhang N, Wang S, Yao J and Shi Y: CRM1 as a new therapeutic target for non-Hodgkin lymphoma. Leuk Res. 39:38–46. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Delman M, Avcı ST, Akçok İ, Kanbur T, Erdal E and Çağır A: Antiproliferative activity of (R)-4'-methylklavuzon on hepatocellular carcinoma cells and EpCAM+/CD133+ cancer stem cells via SIRT1 and Exportin-1 (CRM1) inhibition. Eur J Med Chem. 180:224–237. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Liu X, Chong Y, Liu H, Han Y and Niu M: CRM1 inhibitor S109 suppresses cell proliferation and induces cell cycle arrest in renal cancer cells. Korean J Physiol Pharmacol. 20:161–168. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Daelemans D, Afonina E, Nilsson J, Werner G, Kjems J, De Clercq E, Pavlakis GN and Vandamme AM: A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci USA. 99:14440–14445. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Xu HW, Jia S, Liu M, Li X, Meng X, Wu X, Yu L, Wang M and Jin CY: A low toxic CRM1 degrader: Synthesis and anti-proliferation on MGC803 and HGC27. Eur J Med Chem. 206(112708)2020.PubMed/NCBI View Article : Google Scholar |
